Healthcare
•1072 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (1072)
%
| Company | Market Cap | Price |
|---|---|---|
|
Lilly is a large-cap pharmaceutical company with a globally diversified product portfolio and substantial revenue.
|
$789.93B |
$833.49
-2.86%
|
|
Company's oncology-focused biotech portfolio and cancer therapies (e.g., CAR-VYKTI, bispecifics) represent a major product category.
|
$458.89B |
$190.72
-0.67%
|
|
Skyrizi and Rinvoq are monoclonal antibody therapeutics, directly manufactured and sold by AbbVie in immunology.
|
$431.71B |
$236.56
-1.80%
|
|
Oral-B iO toothbrush is a dental equipment product PG directly sells.
|
$350.95B |
$149.69
-0.82%
|
|
AstraZeneca highlights its Antibody Drug Conjugate (ADC) platform with multiple ADC programs (e.g., Enhertu) and P-Sam in development.
|
$262.04B |
$84.53
-1.28%
|
|
Novo Nordisk is a Large Cap Pharma company that directly develops and sells GLP-1 diabetes/obesity therapies (e.g., Ozempic, Wegovy).
|
$256.75B |
$56.93
-2.84%
|
|
Novartis' oncology portfolio (Kisqali, Scemblix, Pluvicto) is a core revenue driver and growth engine.
|
$252.00B |
$130.00
|
|
Abbott directly manufactures diagnostic equipment and systems (e.g., Alinity N, transfusion diagnostics) as a core business.
|
$230.52B |
$132.57
-1.21%
|
|
Keytruda is a monoclonal antibody cancer therapy and a core revenue driver in Merck's oncology franchise.
|
$200.78B |
$79.96
-0.16%
|
|
Thermo Fisher manufactures diagnostic equipment and analytical instruments (e.g., mass spectrometers, Cryo-EM, lab automation).
|
$198.11B |
$524.80
-1.88%
|
|
Amgen has a leading biosimilars franchise with PAVBLU, WEZLANA, BEKEMV and ongoing biosimilar launches.
|
$156.00B |
$290.13
-2.04%
|
|
Intuitive Surgical's core business is the design, manufacture, and sale of da Vinci surgical robotic systems and associated instruments, i.e., surgical equipment.
|
$153.97B |
$429.59
-3.26%
|
|
Gilead has a deep oncology franchise through Trodelvy and a broader strategy into cancer therapies.
|
$145.76B |
$117.18
-0.40%
|
|
Diagnostic Equipment encompasses instruments like DxC 500i, DXi 9000, and Cepheid platforms used in clinical diagnostics.
|
$144.89B |
$202.46
-1.20%
|
|
Directly manufactures and markets cardiovascular medical devices, including WATCHMAN LAAC and AF ablation products (FARAPULSE).
|
$141.15B |
$95.41
-1.94%
|
|
Orthopedic Devices - core product category including implants and joint replacement systems (e.g., hips, knees, trauma implants).
|
$139.34B |
$364.60
-1.54%
|
|
Pfizer is a large-cap pharma company with a diversified global product portfolio.
|
$137.19B |
$24.09
-0.15%
|
|
Diagnostic Equipment – KLAC's tools function as diagnostic instruments for yield management and defect characterization in semiconductor manufacturing.
|
$129.96B |
$982.75
-6.61%
|
|
Medtronic's core Cardiology Devices portfolio includes leadless pacemakers, ablation catheters, and structural heart implants (e.g., TAVR), driving its largest revenue and growth in cardiovascular care.
|
$122.30B |
$95.45
-1.27%
|
|
Dupixent and Beyfortus are monoclonal antibody therapeutics, a core Sanofi product class.
|
$120.19B |
$98.46
|
|
Vital Signs Monitoring platform and health wearables-related sensing capabilities for patient monitoring.
|
$111.81B |
$225.32
-5.22%
|
|
Vertex's ALYFTREK (CFTR modulator) and TRIKAFTA are oral small-molecule therapeutics for cystic fibrosis, representing a core product category.
|
$104.72B |
$407.79
-1.34%
|
|
Direct sale and distribution of generic drugs, a major CVS drug category.
|
$98.55B |
$77.90
-0.33%
|
|
Medical Device Consumables are disposable items sold/distributed for use with medical devices, a service McKesson provides through its Medical-Surgical Solutions.
|
$95.72B |
$765.08
-0.68%
|
|
Opdivo and the oncology Growth Portfolio are core to Bristol-Myers Squibb's business.
|
$89.46B |
$43.96
-1.83%
|
|
GSK's portfolio includes multiple vaccines (Arexvy, Shingrix, Penmenvy), making Vaccines a core product area.
|
$88.43B |
$21.73
|
|
Diagnostic Equipment reflects ITW's Test & Measurement focus within electronics/testing domains.
|
$71.76B |
$244.93
-1.60%
|
|
Zoetis develops and commercializes vaccines for animals.
|
$62.82B |
$141.11
-1.59%
|
|
Regeneron’s Dupixent and Libtayo represent core monoclonal antibody therapeutics driving a large portion of revenue.
|
$60.96B |
$564.63
-0.82%
|
|
Alnylam's core offerings are RNA interference therapeutics (AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO), defining the primary product category as RNAi Therapeutics.
|
$60.04B |
$460.46
+0.04%
|
|
Verathon’s video laryngoscope and related surgical devices place the company in surgical equipment.
|
$54.73B |
$509.00
-2.25%
|
|
BD markets diagnostic instruments and platforms (e.g., Onclarity HPV assay, FACSDiscover) directly enabling disease detection and analysis.
|
$53.47B |
$186.56
-1.50%
|
|
IDEXX directly manufactures diagnostic equipment (in-clinic analyzers and related systems) used for veterinary diagnostics, a core product line.
|
$49.55B |
$616.15
-2.00%
|
|
Core focus on immunology therapeutics and autoimmune disease treatments (VYVGART and pipeline).
|
$47.65B |
$796.92
-0.76%
|
|
Takeda's dengue vaccine QDENGA demonstrates a clear vaccines product line with strong global demand.
|
$43.58B |
$27.33
-2.62%
|
|
Takeda is a Large Cap Pharmaceutical company with a diversified global pharma portfolio.
|
$43.47B |
$13.71
-1.01%
|
|
Edwards Lifesciences' core offerings are cardiology devices, including transcatheter heart valves and other structural heart therapies.
|
$43.37B |
$73.94
-1.58%
|
|
Offers over-the-counter pain relief/analgesics under its brands.
|
$41.10B |
$9.00
-0.22%
|
|
Agilent's core offering is analytical instruments and diagnostic equipment (GC/GCMS, LC/LCMS) used in life sciences, diagnostics, and applied markets.
|
$40.00B |
$140.11
-0.12%
|
|
NightOwl and at-home sleep apnea diagnostic capabilities constitute Diagnostic Equipment offerings.
|
$39.88B |
$272.00
-2.10%
|
|
Cardinal Health operates BioPharma Solutions, a contract manufacturing organization that provides outsourced pharmaceutical manufacturing services.
|
$37.44B |
$156.88
-0.61%
|
|
Alcon directly designs, manufactures, and sells ophthalmology devices including Unity VCS, PanOptix Pro IOL, Voyager DSLT, Clareon-based IOLs, LumiThera Valeda system, and STAAR EVO ICLs.
|
$35.64B |
$72.05
-3.44%
|
|
BeOne Medicines is an oncology-focused biotech company delivering cancer therapies, including BRUKINSA and TEVIMBRA.
|
$34.59B |
$320.10
-3.00%
|
|
IQVIA operates as a Contract Research Organization delivering outsourced R&D services across clinical research and real-world evidence.
|
$34.28B |
$198.17
-2.56%
|
|
GE HealthCare manufactures and sells Medical Imaging devices (CT, MR, ultrasound) as core product lines.
|
$32.51B |
$71.01
-4.05%
|
|
Tylenol and other OTC analgesics are core self-care offerings that Kenvue directly manufactures and sells.
|
$31.52B |
$16.18
-1.49%
|
|
Insmed operates as a large-cap pharmaceutical company with a multi-asset pipeline and ARIKAYCE as a key revenue driver.
|
$29.57B |
$162.33
-1.08%
|
|
Philips' primary product line includes medical imaging hardware and imaging modalities (MRI, CT, ultrasound) used for diagnostics.
|
$26.88B |
$27.35
|
|
MTD directly manufactures imaging, laboratory and point-of-care diagnostic instruments (diagnostic equipment).
|
$26.47B |
$1273.67
-2.72%
|
|
DexCom's CGM devices are patient monitoring devices providing real-time glucose data.
|
$25.53B |
$65.12
-4.45%
|
|
Veralto directly provides diagnostic equipment and instrumentation for water analysis (e.g., Hach).
|
$25.25B |
$101.87
-0.97%
|
|
BioNTech directly develops and commercializes vaccines, including its COVID-19 vaccine franchise and ongoing vaccine-related therapies.
|
$24.47B |
$102.06
-2.54%
|
|
STERIS offers medical device consumables such as detergents and sterility assurance products tied to its infection-prevention offerings.
|
$23.84B |
$239.42
-1.77%
|
|
Labcorp operates as an outsourced drug development and central-laboratory service provider, i.e., a Contract Research Organization (CRO) in biopharma.
|
$23.26B |
$277.88
-0.11%
|
|
Teva is a leading generic drug manufacturer with a broad portfolio and ongoing growth in generic sales.
|
$22.95B |
$20.01
+0.05%
|
|
Signatera and related cfDNA tests operate as liquid biopsy diagnostic tests detecting circulating tumor DNA.
|
$22.07B |
$161.61
+0.94%
|
|
Waterpik water flossers and dental devices purchased/sold by CHD align with Dental Equipment.
|
$21.60B |
$87.70
-0.17%
|
|
The system relies on CGM data for insulin delivery, reflecting Patient Monitoring capabilities.
|
$21.53B |
$305.98
-0.90%
|
|
Direct product: LEQEMBI is Biogen's monoclonal antibody therapy for Alzheimer's disease.
|
$21.48B |
$146.57
-2.29%
|
|
Genmab operates as a biotechnology company focused on oncology with proprietary antibody platforms and therapies.
|
$21.05B |
$31.81
-0.28%
|
|
Contract Manufacturing Organizations captures the CDMO-like manufacturing services via the Pharmaceutics International acquisition.
|
$20.82B |
$193.99
-5.75%
|
|
Quest Diagnostics offers liquid biopsy diagnostic tests (e.g., Haystack MRD) and other circulating biomarker-based assays, a major liquid biopsy product category.
|
$20.55B |
$184.07
+0.97%
|
|
Acquisition of Atomic Alchemy to produce radioisotopes and VIPR medical/industrial isotopes.
|
$20.49B |
$147.16
+6.88%
|
|
UTHR's core PAH/PH-ILD prostacyclin therapies drive the revenue base, including Tyvaso DPI, Nebulized Tyvaso, Remodulin/Remunity, and Orenitram.
|
$19.85B |
$440.00
-1.27%
|
|
Zimmer Biomet's core business is orthopedic implants and devices (hips, knees) and related orthopedic products.
|
$19.84B |
$99.20
-1.08%
|
|
Waters manufactures and sells diagnostic equipment (analytical instruments such as LC/UPLC and MS systems) used in regulated laboratory testing.
|
$19.70B |
$331.00
+0.16%
|
|
Genmab is a oncology-focused biotechnology company, generating revenue from cancer therapeutics (EPKINLY, Tivdak) and a pipeline centered on anticancer biologics.
|
$19.49B |
$315.00
|
|
West's GLP-1 self-injection device platforms (Auto-Injector Devices) are a core product line.
|
$18.81B |
$261.77
-1.19%
|
|
Tenet provides hospital services, including inpatient and outpatient hospital operations.
|
$17.61B |
$189.58
-2.87%
|
|
BWXT's Medical segment produces radiopharmaceuticals and nuclear medicine isotopes used in diagnostics and therapy.
|
$17.37B |
$190.08
-2.82%
|
|
RS&I provides diagnostic equipment and repair information platforms used by professional technicians.
|
$17.12B |
$327.33
-1.72%
|
|
Primary business includes Laboratory Testing & Advisory Services, including genomics and hereditary testing via Ambry Genetics.
|
$16.69B |
$96.39
-4.47%
|
|
Fluke and other Fortive instrumentation are diagnostic/testing equipment sold to customers.
|
$16.25B |
$47.80
-3.45%
|
|
Incyte's core business includes small-molecule therapeutics (e.g., oral JAK inhibitors) and an actively developed pipeline of other oral NCEs.
|
$16.22B |
$83.80
-1.42%
|
|
Summit's direct product focus is ivonescimab in oncology, licensed for development and commercialization, making Biotech - Oncology a core segment.
|
$15.86B |
$21.35
-6.28%
|
|
Core product category including dialysis devices and dialyzers used for blood purification in renal therapy.
|
$15.80B |
$53.85
|
|
Directly produces blood purification devices (dialysis machines) and related dialysis equipment.
|
$15.74B |
$26.82
-1.76%
|
|
Core product category including joint implants (hip/knee) and related orthopedic devices.
|
$15.42B |
$17.71
|
|
ICON is a Contract Research Organization (CRO) providing outsourced drug development services across all clinical trial phases and expanded scale via the PRA acquisition.
|
$15.15B |
$183.49
-2.46%
|
|
Illumina directly manufactures sequencing instruments (e.g., NovaSeq X, MiSeq i100 Plus), which are diagnostic equipment.
|
$14.86B |
$93.86
-2.73%
|
|
Hologic's Panther Fusion and other diagnostic instruments place it in the Diagnostic Equipment category.
|
$14.78B |
$67.92
+0.94%
|
|
INGREZZA and the Neurocrine CNS portfolio are driven by oral small-molecule therapeutics, including a broad pipeline of additional small-molecule CNS agents.
|
$14.51B |
$146.95
+0.38%
|
|
Directly provides Laboratory Testing & Advisory Services (TIC) and related testing/advisory work.
|
$14.47B |
$72.16
-1.57%
|
|
Medpace is a full-service Contract Research Organization (CRO) delivering outsourced clinical development and regulatory services for Phase I–IV trials.
|
$14.41B |
$501.22
-3.28%
|
|
CooperVision eye-care products (daily silicone hydrogel lenses, MiSight, etc.) are ophthalmology devices sold as eye-care medical devices.
|
$14.02B |
$69.75
-0.53%
|
|
Dental Equipment is a primary product category for Solventum's Dental Solutions segment, including 3D-printed components like attachments.
|
$12.91B |
$74.29
-0.42%
|
|
The company offers Laboratory Testing & Advisory Services, including PFAS testing validated with regulatory agencies, aligning with PFAS remediation and environmental testing capabilities.
|
$12.53B |
$233.95
+0.58%
|
|
Owns/operates lab testing facility Trybe Labs enabling diagnostics and data for treatment customization.
|
$12.08B |
$53.95
-7.45%
|
|
Ascendis is cornerstone in rare-disease therapies with marketed products YORVIPATH and SKYTROFA and a pipeline (TransCon CNP) targeting rare conditions, matching the Biotech - Rare Diseases theme.
|
$12.06B |
$209.55
-2.16%
|
|
Dr. Reddy's is a leading producer of generic drugs with a broad, global portfolio.
|
$11.96B |
$14.34
+1.63%
|
|
Baxter's product portfolio includes surgical equipment and devices (e.g., Hemopatch sealing hemostat) used in operating rooms.
|
$11.26B |
$21.95
-3.09%
|
|
Viatris is a leading manufacturer of generic drugs with a diversified portfolio of off-patent medicines.
|
$11.17B |
$9.52
-0.42%
|
|
Ionis has multiple late-stage and marketed assets across rare diseases (e.g., FCS, HAE, Alexander disease, Angelman), forming a core rare-disease portfolio.
|
$11.14B |
$69.97
-0.04%
|
|
EXAS directly develops and sells diagnostic tests and related laboratory testing services for cancer screening and oncology diagnostics.
|
$11.01B |
$58.34
-2.11%
|
|
Roivant's immunology portfolio (FcRn inhibitors IMVT-1402 and batoclimab) targets autoimmune/inflammatory diseases, aligning with Immunology Therapeutics.
|
$10.90B |
$16.04
-0.50%
|
|
BBP-812 is an AAV9 gene therapy for Canavan disease, directly produced by BridgeBio.
|
$10.54B |
$55.49
+1.20%
|
|
QIAGEN sells diagnostic equipment and platforms (QIAstat-Dx, QIAcuity, and automation systems).
|
$10.49B |
$46.85
-1.10%
|
|
Exelixis develops oncology-focused biotech therapies, including small-molecule TKIs and antibody-based modalities within cancer.
|
$10.40B |
$38.15
-1.34%
|
|
Moderna directly develops and sells vaccines using its mRNA platform (e.g., Spikevax and pipeline vaccines like mRESVIA and mRNA-1283), which are core products highlighted in the article.
|
$10.38B |
$26.83
-3.42%
|
|
Walgreens sells OTC pain relief and analgesics as a major consumer health product category.
|
$10.36B |
$11.98
|
Showing page 1 of 11 (1072 total stocks)
Loading industry metrics...
Loading comparison data...
